Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Molecular Characterization and Antifungal Susceptibilitytesting of Candida Nivariensis From Blood Samples – an Iranian Multicentre Study and a Review of the Literature Publisher Pubmed



Arastehfar A1 ; Daneshnia F1 ; Salehi MR2 ; Zarrinfar H3 ; Khodavaisy S4, 6 ; Haas PJ5 ; Roudbary M4, 6 ; Najafzadeh MJ7 ; Zomorodian K8 ; Charsizadeh A9 ; Brouwer C1, 10, 11 ; Pan W12 ; Hagen F1, 5 ; Boekhout T1, 13
Authors
Show Affiliations
Authors Affiliations
  1. 1. Westerdijk Fungal Biodiversity Institute, Utrecht, Netherlands
  2. 2. Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  4. 4. Department of Medical Mycology and Parasitology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands
  6. 6. Department of Medical Mycology and Parasitology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Medical Mycology and Parasitology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  8. 8. Basic Sciences in Infectious Diseases Research Center, and Department of Medical Mycology and Parasitology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  9. 9. Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  10. 10. BioAware Life Sciences Data Management Software, Belgium
  11. 11. CBMR Scientific Inc, Edmonton, Canada
  12. 12. Department of Dermatology, Shanghai Key Laboratory of Molecular Medical Mycology, Shanghai Institute of Medical Mycology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China
  13. 13. Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, Netherlands

Source: Journal of Medical Microbiology Published:2019


Abstract

Purpose. Identification of the emerging yeast species Candida nivariensis among presumptively identified Iranian Candida glabrata isolates. Methodology. Clinical C. glabrata species complex isolates from blood (n=100; 46.9%), vaginal swabs (n=20; 9.4%), bronchoalveolar lavage (n=10; 4.7%) and sputum (n=12; 5.6%) from 68 patients from Iran were investigated. Isolates were characterized by CHROMagar, multiplex PCRs, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), amplified fragment length polymorphism (AFLP) fingerprinting, internal transcribed spacer (ITS)/large subunit (LSU) rDNA and FKS1/FKS2 sequencing, and the European Committee on Antimicrobial Susceptibility Testing broth microdilution method. A comprehensive literature review was conducted and all the relevant clinical and microbiological data were collected. Results. Four C. nivariensis isolates were recovered from blood samples of three subjects and were all consistently identified by nine-plex PCR, Bruker MALDI-TOF MS, and LSU and ITS rDNA sequencing. AFLP genotyping clustered the isolates into two groups. Sequencing of the FKS1 and FKS2 hotspots showed no accountable amino acid substitutions. All isolates were susceptible to amphotericin B, fluconazole, itraconazole, posaconazole, voriconazole, anidulafungin and micafungin. Conclusion. In total, 4 out of 213 clinical C. glabrata species complex candidemia isolates were C. nivariensis. Improvement of the BioMerieux Vitek MS database is required to accurately identify C. nivariensis and it is advised to alternatively use CHROMagar and/or PCR-based techniques. As other species within the Nakaseomyces clade may cause infection and showed high MIC values for antifungals, inclusion of their spectra into the MALDI-TOF MS database seems relevant. Due to developing resistance to fluconazole and insufficient efficacy of caspofungin, the combination of catheter removal plus treatment with caspofungin, or voriconazole, or micafungin might be effective for patients. © 2019, Microbiology Society. All rights reserved.
Experts (# of related papers)